758-P: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset
Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent a paradigm shift in treating obesity. The substantial weight loss observed in clinical trials improves weight-related comorbidities. However, weight loss reported in the real world has been less than that seen in clinical trials. One hypothesis for this gap is that patients may not complete the […]
292-OR: Oral Semaglutide and Cardiovascular Outcomes by Baseline A1C and BMI in People with Type 2 Diabetes in the SOUL Trial
Introduction and Objective: In SOUL (NCT03914326), oral semaglutide (sema) 14 mg QD, a GLP-1 receptor agonist, reduced major adverse cardiovascular (CV) event (MACE) risk by 14%. GLP-1RAs are routinely prescribed to reduce A1c and BMI in type 2 diabetes (T2D). Whether the CV benefits of oral sema are influenced by baseline A1c or BMI is […]
How GLP-1 drugs like semaglutide have revolutionised obesity treatment
Post Content
The microbial tryptophan metabolite indole acts on the gastrointestinal tract to improve glucose homeostasis by enhancing GLP-1 secretion and L-cell differentiation
Aims/hypothesis: Growing evidence implicates gut microbiota-derived metabolites in metabolic homeostasis. Indole, a microbial tryptophan metabolite, has been reported to enhance Glucagon-like peptide-1 (GLP-1) secretion in vitro, and its derivatives have been inversely associated with risk of type 2 diabetes (T2D). We hypothesised that indole acts via the gastrointestinal tract to modulate glucose homeostasis, and aimed […]
Stung By High Prices, Americans Make Their Own Weight-Loss Drugs
SAN FRANCISCO (Reuters) – In what she calls the “wild west” of obesity medicines, Missouri-based Amy Spencer is a pioneer. Each week, the mother of two injects herself with weight-loss drugs, two of which are in clinical trials and not yet approved for sale by the U.S. Food and Drug Administration. One comes mixed with […]
Ozempic And Plastic Surgery Dominate Jeff Bezos’s Wedding As Skinny Stars Shut Down Venice
Hollywood’s upper crust has converged on Venice for the three-day wedding extravaganza of Amazon mogul Jeff Bezos and Lauren Sanchez, with a cluster of snatched waists drawing attention and fueling Ozempic speculation. Photographs of the event showed a bustle of activity as various A-listers boarded boats and water taxis—some flamboyant and daring the photographers, while […]
J&J dealt blow in fight over its 340B rebate model
A federal judge said the government did not run afoul of the law when it required Johnson & Johnson to seek approval before implementing its proposed 340B rebate model. The Friday decision marks another court …
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Novo Nordisk markets its semaglutide drugs as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes (T2D) and as Wegovy injection for weight management. Lilly markets its dual GIP and GLP-1 receptor agonist, […]
With China approval, Lilly and Innovent’s mazdutide breaks into new class for GLP-1 obesity drugs
With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap the rewards in the near term.
The GLP-1 Weight Loss Drug Ozempic Is Reportedly Giving Men A Lot To Brag About, Down Under
Imagine getting rid of your persistent fat layers, while gaining girth down under. That’s a contemporary equivalent to the fabled fountain of youth, and a special class of weight loss drugs that leverage the GLP-1 hormone – such as Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound – are now being billed as the conduits for […]